Pheochromocytoma-Pipeline Review, H1 2017

Pheochromocytoma-Pipeline Review, H1 2017


  • Products Id :- GMDHC9279IDB
  • |
  • Pages: 80
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pheochromocytoma-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma-Pipeline Review, H1 2017, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pheochromocytoma-Overview

Pheochromocytoma-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pheochromocytoma-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pheochromocytoma-Companies Involved in Therapeutics Development

Advanced Accelerator Applications SA

Exelixis Inc

MediaPharma srl

OctreoPharm Sciences GmbH

Pfizer Inc

Progenics Pharmaceuticals Inc

Tarveda Therapeutics Inc

Valeant Pharmaceuticals International Inc

Pheochromocytoma-Drug Profiles

cabozantinib s-malate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iobenguane sulfate I 131-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LMP-400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lutathera-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metyrosine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPBF-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONC-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPS-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEN-221-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-43126-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pheochromocytoma-Dormant Projects

Pheochromocytoma-Product Development Milestones

Featured News & Press Releases

Mar 30, 2017: Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA

Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA

Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra

Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015

Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma

Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015

Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma

Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma

Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications

Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Pheochromocytoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Pheochromocytoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pheochromocytoma-Pipeline by Advanced Accelerator Applications SA, H1 2017

Pheochromocytoma-Pipeline by Exelixis Inc, H1 2017

Pheochromocytoma-Pipeline by MediaPharma srl, H1 2017

Pheochromocytoma-Pipeline by OctreoPharm Sciences GmbH, H1 2017

Pheochromocytoma-Pipeline by Pfizer Inc, H1 2017

Pheochromocytoma-Pipeline by Progenics Pharmaceuticals Inc, H1 2017

Pheochromocytoma-Pipeline by Tarveda Therapeutics Inc, H1 2017

Pheochromocytoma-Pipeline by Valeant Pharmaceuticals International Inc, H1 2017

Pheochromocytoma-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Advanced Accelerator Applications SA, Exelixis Inc, MediaPharma srl, OctreoPharm Sciences GmbH, Pfizer Inc, Progenics Pharmaceuticals Inc, Tarveda Therapeutics Inc, Valeant Pharmaceuticals International Inc

Pheochromocytoma Therapeutic Products under Development, Key Players in Pheochromocytoma Therapeutics, Pheochromocytoma Pipeline Overview, Pheochromocytoma Pipeline, Pheochromocytoma Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com